Smart app aims to optimize heart failure meds

NCT ID NCT05858320

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This completed Phase 3 trial tested a web application called SmartHF in 225 adults with heart failure and reduced ejection fraction. The app analyzes patient data and gives personalized medication recommendations that patients can share with their doctor. The goal was to see if using the app improves medication scores over 12 weeks compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
SmartHF web application (adaptive medication recommendations)
What this could lead to
If successful, this could provide a simple, patient-friendly tool to help doctors and patients optimize heart failure medications, potentially improving outcomes.
What could go wrong
This is a completed trial with 225 participants, so results are available but may not apply to all heart failure patients. The app only recommends medications; it does not prescribe them, so real-world impact depends on doctor uptake.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory University, Grady Hospital

    Atlanta, Georgia, 30303, United States

  • Henry Ford Hospital and Health System

    Detroit, Michigan, 48202, United States

  • Trinity Healthcare St. Joseph Mercy Ann Arbor

    Ypsilanti, Michigan, 48197, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • Washington University, Barns Jewish Hospital

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.